Cardiovascular Research

Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study.

Authors: Astrid M Suchy-Dicey|||W T Longstreth|||Kristoffer Rhoads|||Jason Umans|||Dedra Buchwald|||Thomas Grabowski|||Kaj Blennow|||Eric Reiman|||Henrik Zetterberg

Affiliations: + Expand

Abstract

Identification of Alzheimer's disease (AD) needs inexpensive, noninvasive biomarkers, with validation in all populations.

---

Chemical List

Amyloid beta-Peptides|||Biomarkers|||tau Proteins

---

Reference List

Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562. doi:10.1016/j.jalz.2018.02.018|||Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the early detection and progression of Alzheimer's disease. Neurotherapeutics. 2017;14(1):35‐53. doi:10.1007/s13311-016-0481-z|||Tsvetkova DZ, Bergquist SH, Parker MW, et al. Fear and uncertainty do not influence reported willingness to undergo lumbar punctures in a U.S. Multi‐cultural cohort. Front Aging Neurosci. 2017;9:22. doi:10.3389/fnagi.2017.00022|||Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta‐analysis. Lancet Neurol. 2016;15(7):673‐684. doi:10.1016/S1474-4422(16)00070-3|||Suchy‐Dicey AM, Shibata D, Best LG, et al. Cranial magnetic resonance imaging in elderly American Indians: design, methods, and implementation of the cerebrovascular disease and its consequences in American Indians study. Neuroepidemiology. 2016;47(2):67‐75. doi:10.1159/000443277|||Suchy‐Dicey AM, Oziel K, Sawyer C, et al. Educational and clinical associations with longitudinal cognitive function and brain imaging in American Indians: the strong heart study. Neurology. 2022;99(24):e2637‐e2647. doi:10.1212/WNL.0000000000201261|||Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease‐related blood‐based biomarkers: results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484‐1497. doi:10.1002/alz.12510|||Cullen NC, Janelidze S, Mattsson‐Carlgren N, et al. Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimers Dement. 2022. Epub ahead of print. PMID: 35699240; PMCID: PMC9747985. doi:10.1002/alz.12706|||Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422‐433. doi:10.1016/S1474-4422(20)30071-5|||Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test (CVLT‐II). 2nd ed. Adult Version. The Psychological Corporation; 2000.|||Teng EL, Chang Chui H. The Modified Mini‐Mental (3MS) Examination. Journal Clinical Psychiatry. 1987;48(8):314‐318.|||Benton AL, Hansher K. Multilingual Aphasia Examination. 2nd ed. AJA Associates; 1976.|||Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210‐216. doi:10.1097/01.wad.0000213865.09806.92|||Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695‐699. doi:10.1111/j.1532-5415.2005.53221.x|||Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011;49(1):43‐48. doi:10.1016/j.neuropsychologia.2010.10.026|||Llinas‐Regla J, Vilalta‐Franch J, Lopez‐Pousa S, Calvo‐Perxas L, Torrents Rodas D, Garre‐Olmo J. The trail making test. Assessment. 2017;24(2):183‐196. doi:10.1177/1073191115602552|||Liew TM. Developing a brief neuropsychological battery for early diagnosis of cognitive impairment. J Am Med Dir Assoc. 2019;20(8):1054 e11‐1054 e20. doi:10.1016/j.jamda.2019.02.028|||Ivanova I, Salmon DP, Gollan TH. The multilingual naming test in Alzheimer's disease: clues to the origin of naming impairments. J Int Neuropsychol Soc. 2013;19(3):272‐283. doi:10.1017/S1355617712001282|||North KE, Goring HH, Cole SA, et al. Linkage analysis of LDL cholesterol in American Indian populations: the Strong Heart Family Study. J Lipid Res. 2006;47(1):59‐66. doi:10.1194/jlr.M500395-JLR200|||Kataoka S, Robbins DC, Cowan LD, et al. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 1996;16(8):918‐925.|||Rothberg MB, Kehoe ED, Courtemanche AL, et al. Recognition and management of chronic kidney disease in an elderly ambulatory population. J Gen Intern Med. 2008;23(8):1125‐1130. doi:10.1007/s11606-008-0607-z|||Tsiknia AA, Edland SD, Sundermann EE, et al. Sex differences in plasma p‐Tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression. Mol Psychiatry. 2022;27(10):4314‐4322. doi:10.1038/s41380-022-01675-8|||Windon C, Iaccarino L, Mundada N, et al. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimers Dement. 2022;14(1):e12315. doi:10.1002/dad2.12315|||Gu L, Guo Z. Alzheimer's Abeta42 and Abeta40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126(3):305‐311. doi:10.1111/jnc.12202|||Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Transl Psychiatry. 2021;11(1):27. doi:10.1038/s41398-020-01137-1|||Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid‐beta but not tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505‐3516. doi:10.1093/brain/awab223|||Mielke MM, Syrjanen JA, Blennow K, et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252‐e260. doi:10.1212/WNL.0000000000007767|||Simren J, Andreasson U, Gobom J, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years. Brain Commun. 2022;4(4):fcac174. doi:10.1093/braincomms/fcac174|||Harp C, Thanei GA, Jia X, et al. Development of an age‐adjusted model for blood neurofilament light chain. Ann Clin Transl Neurol. 2022;9(4):444‐453. doi:10.1002/acn3.51524|||Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14(1):26. doi:10.1186/s13195-021-00942-0|||Coomans EM, Verberk IMW, Ossenkoppele R, et al. A head‐to‐head comparison between plasma pTau181 and tau PET Along the Alzheimer's disease continuum. J Nucl Med. 2023;64(3):437‐443. doi:10.2967/jnumed.122.264279|||Benussi A, Cantoni V, Rivolta J, et al. Classification accuracy of blood‐based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration. Alzheimers Res Ther. 2022;14(1):155. doi:10.1186/s13195-022-01094-5|||Suchy‐Dicey A, Howard B, Longstreth WT Jr, Reiman EM, Buchwald D. APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: data from the Strong Heart Study. Alzheimers Dement. 2022;18(12):2518‐2526. doi:10.1002/alz.12573|||Suchy‐Dicey AM, Muller CJ, Madhyastha TM, et al. Telomere length and magnetic resonance imaging findings of vascular brain injury and Central Brain Atrophy: the Strong Heart Study. Am J Epidemiol. 2018;187(6):1231‐1239. doi:10.1093/aje/kwx368